Drugs / OXA
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01605305 Background | Sep 2008 → Jan 2012 | esophageal squamous cell carcinoma | Fudan University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OXA | “OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h” NCT01605305 ↗ |
| Route | Intravenous | “OXA 100mg/m2 ivgtt 2h d1” NCT01605305 ↗ |